Genetically engineered vaccines

[1]  M. Gelb,et al.  Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity , 2004, Protein science : a publication of the Protein Society.

[2]  M. Gajhede,et al.  Allergy Vaccine Engineering: Epitope Modulation of Recombinant Bet v 1 Reduces IgE Binding but Retains Protein Folding Pattern for Induction of Protective Blocking-Antibody Responses1 , 2004, The Journal of Immunology.

[3]  H. Grönlund,et al.  Vaccination with genetically engineered allergens prevents progression of allergic disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Durham,et al.  Mechanisms of immunotherapy. , 2004, The Journal of allergy and clinical immunology.

[5]  R. Valenta,et al.  Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 71 , 2004, The Journal of Immunology.

[6]  M. Marinaro,et al.  The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  Susanna Repo,et al.  Construction of Hevein (Hev b 6.02) with Reduced Allergenicity for Immunotherapy of Latex Allergy by Comutation of Six Amino Acid Residues on the Conformational IgE Epitopes 1 , 2004, The Journal of Immunology.

[8]  R. Valenta,et al.  Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1 , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[9]  P. Neudecker,et al.  Mutational epitope analysis of Pru av 1 and Api g 1, the major allergens of cherry (Prunus avium) and celery (Apium graveolens): correlating IgE reactivity with three-dimensional structure. , 2003, The Biochemical journal.

[10]  C. Ebner,et al.  Allergen‐specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy , 2003, Immunology.

[11]  M. Gajhede,et al.  Dominating IgE-Binding Epitope of Bet v 1, the Major Allergen of Birch Pollen, Characterized by X-ray Crystallography and Site-Directed Mutagenesis , 2003, The Journal of Immunology.

[12]  R. Valenta,et al.  Prevention of allergen‐specific IgE production and suppression of an established Th2‐type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch‐pollen allergen , 2003, European Journal of Immunology.

[13]  A. Burks,et al.  Engineered Recombinant Peanut Protein and Heat-Killed Listeria monocytogenes Coadministration Protects Against Peanut-Induced Anaphylaxis in a Murine Model1 , 2003, The Journal of Immunology.

[14]  M. Chapman,et al.  High-level expression of immunoreactive recombinant cat allergen (Fel d 1): Targeting to antigen-presenting cells. , 2002, The Journal of allergy and clinical immunology.

[15]  M. Andersson,et al.  Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild‐type in patients with allergic rhinitis , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  R. Valenta,et al.  The FASEB Journal express article 10.1096/fj.01-1012fje. Published online June 21, 2002. , 2022 .

[17]  H. Hosokawa,et al.  DNA vaccine using invariant chain gene for delivery of CD4+ T cell epitope peptide derived from Japanese cedar pollen allergen inhibits allergen‐specific IgE response , 2002, European journal of immunology.

[18]  R. Helm,et al.  Modification of Peanut Allergen Ara h 3: Effects on IgE Binding and T Cell Stimulation , 2002, International Archives of Allergy and Immunology.

[19]  R. Valenta,et al.  Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE‐binding capacity: candidates for grass pollen‐specific immunotherapy , 2002, European journal of immunology.

[20]  A. Scheynius,et al.  A Hypoallergenic Derivative of the Major Allergen of the Dust Mite Lepidoglyphus destructor, Lep d 2.6Cys, Induces Less IgE Reactivity and Cellular Response in the Skin than Recombinant Lep d 2 , 2001, International Archives of Allergy and Immunology.

[21]  P. Hufnagl,et al.  Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  R. Fritsché,et al.  Suppression of Specific and Bystander IgE Responses in a Mouse Model of Oral Sensitization to β-Lactoglobulin , 2001, International Archives of Allergy and Immunology.

[23]  S. S. Kwon,et al.  The effect of vaccination with DNA encoding murine T‐cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis , 2001, Allergy.

[24]  N. Serizawa,et al.  Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. , 2001, The Journal of allergy and clinical immunology.

[25]  A. Kagey‐Sobotka,et al.  Recombinant Allergens with Reduced Allergenicity but Retaining Immunogenicity of the Natural Allergens: Hybrids of Yellow Jacket and Paper Wasp Venom Allergen Antigen 5s1 , 2001, The Journal of Immunology.

[26]  R. Helm,et al.  Engineering, Characterization and in vitro Efficacy of the Major Peanut Allergens for Use in Immunotherapy , 2001, International Archives of Allergy and Immunology.

[27]  H. Renz,et al.  Mucosal Tolerance Induction with Hypoallergenic Molecules in a Murine Model of Allergic Asthma , 2001, International Archives of Allergy and Immunology.

[28]  D. Salunke,et al.  Crystal Structure of an Antibody Bound to an Immunodominant Peptide Epitope: Novel Features in Peptide-Antibody Recognition1 , 2000, The Journal of Immunology.

[29]  C. Akdis,et al.  T Cell Epitope-Containing Hypoallergenic Recombinant Fragments of the Major Birch Pollen Allergen, Bet v 1, Induce Blocking Antibodies1 , 2000, The Journal of Immunology.

[30]  F. Inagaki,et al.  Effects of proline mutations in the major house dust mite allergen Der f 2 on IgE-binding and histamine-releasing activity. , 2000, European journal of biochemistry.

[31]  Yoshimasa Tanaka,et al.  C8/119S Mutation of Major Mite Allergen Derf-2 Leads to Degenerate Secondary Structure and Molecular Polymerization and Induces Potent and Exclusive Th1 Cell Differentiation1 , 2000, The Journal of Immunology.

[32]  Oster,et al.  Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild‐type by skin prick and intradermal testing: results obtained in a French population , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[33]  M. Gajhede,et al.  Dominant Epitopes and Allergic Cross-Reactivity: Complex Formation Between a Fab Fragment of a Monoclonal Murine IgG Antibody and the Major Allergen from Birch Pollen Bet v 11 , 2000, The Journal of Immunology.

[34]  R. Valenta,et al.  Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. , 2000, The Journal of allergy and clinical immunology.

[35]  J. Punnonen.  Molecular Breeding of Allergy Vaccines and Antiallergic Cytokines , 2000, International Archives of Allergy and Immunology.

[36]  Rautiainen,et al.  Mutant derivatives of the main respiratory allergen of cow are less allergenic than the intact molecule , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  M. Schlaak,et al.  "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. , 1999, Journal of immunology.

[38]  P. Bhalla,et al.  Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy , 1998, FEBS letters.

[39]  M. Suko,et al.  Hyposensitization to allergic reaction in rDer f 2‐sensitized mice by the intranasal administration of a mutant of rDer f 2, C8/119S , 1998, Clinical and experimental immunology.

[40]  A. Burks,et al.  Biochemical and Structural Analysis of the IgE Binding Sites on Ara h1, an Abundant and Highly Allergenic Peanut Protein* , 1998, The Journal of Biological Chemistry.

[41]  G. Casari,et al.  Modulation of IgE reactivity of allergens by site‐directed mutagenesis: potential use of hypoallergenic variants for immunotherapy , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  A. Mori,et al.  Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy , 1997, Nature Biotechnology.

[43]  R. Helm,et al.  Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. , 1997, Archives of biochemistry and biophysics.

[44]  M. Chapman,et al.  Localization of antigenic sites on Der p 2 using oligonucleotide‐directed mutagenesis targeted to predicted surface residues , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[45]  R. Valenta,et al.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. , 1997, The Journal of clinical investigation.

[46]  R. Helm,et al.  Mapping and mutational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity. , 1997, European journal of biochemistry.

[47]  A. Mori,et al.  Determination of the N- and C-terminal sequences required to bind human IgE of the major house dust mite allergen Der f 2 and epitope mapping for monoclonal antibodies. , 1997, Molecular immunology.

[48]  M. Chapman,et al.  Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. , 1996, Molecular immunology.